查詢結果分析
相關文獻
- 抗精神病長效針劑之臨床應用與安全性評估
- Paliperidone Palmitate長效針劑探討
- 抗精神病長效針劑之臨床應用與安全性評估
- 結核病與思覺失調症
- Improvement of Tardive Dyskinesia and Tardive Dystonia in a Schizophrenic Female Patient Using a Low-dose Aripiprazole
- Refeeding Syndrome in Schizophrenia
- Renaming Schizophrenia in Far East Asian Countries
- 思覺失調症病患之主要照顧者復原力與健康狀態之探討
- Anemia Secondary to Valproic Acid in a Female Patient with Schizoaffective Disorder
- 體感式電玩介入對慢性思覺失調症病人健康體適能之成效
頁籤選單縮合
題 名 | Paliperidone Palmitate長效針劑探討=Introduction of Long-acting Injectable Paliperidone Palmitate |
---|---|
作 者 | 王仞寒; 鄭淑文; 鄭淑文; | 書刊名 | 藥學雜誌 |
卷 期 | 35:3=140 2019.09[民108.09] |
頁 次 | 頁87-92 |
分類號 | 418.21 |
關鍵詞 | 抗精神病長效針劑; 思覺失調症; Paliperidone palmitate; Long-acting injection; NanoCrystal technology; |
語 文 | 中文(Chinese) |
中文摘要 | 抗精神病長效針劑是作為預防思覺失調症病人復發的有效方法。Paliperidone palmitate long-acting injection (paliperidone LAI) 為全球第一個上市,可維持一個月療 效的非典型抗精神病長效針劑,其主成分 paliperidone palmitate 通過奈米結晶體技術 (NanoCrystal technology) 達到緩釋藥物的效果。研究顯示,paliperidone LAI 長效針劑 相較於常見的口服藥物有較佳的預防復發效果,此藥物可提供臨床醫護人員治療思覺 失調症一個有效的治療選項。 |
英文摘要 | Long-acting injectable antipsychotics are considered as one of the most effective treatment options for relapse prevention in schizophrenia patients. Paliperidone palmitate long-acting injection (paliperidone LAI) is the first once-monthly atypical long-acting injectable antipsychotic agent, the active ingredient of which, paliperidone palmitate, is able to be consistently released for one month via NanoCrystal technology. Previous studies showed that paliperidone LAI is able to reduce the risk of relapse in comparison with oral antipsychotics; therefore, it can be a desirable treatment choice for health care professionals to cure schizophrenia patients. |
本系統中英文摘要資訊取自各篇刊載內容。